NCT06544499招募中3 期
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- argenx
- 入组人数
- 69
- 试验地点
- 178
- 主要终点
- Extent of disease control, defined as the number of cumulative weeks during the 24-week Double-Blinded Treatment Period with platelet counts of at least 50 × 10^9/L
研究概览
简要总结
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks.
More information can be found here: https://clinicaltrials.argenx.com/advancenext
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is at least 18 years of age and the local legal age of consent for clinical studies when signing the informed consent form (ICF).
- •Has documented baseline mean platelet count of <30 x 10^9/L before randomization
- •Has a documented duration of primary immune thrombocytopenia (ITP) of more than 12 months on the date of informed consent form (ICF) signature.
- •Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, intravenous immunoglobulin (IVIg), anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.
- •Has documented insufficient response to a prior ITP treatment (the specific criteria can be found in the protocol).
- •Has documented prior response defined as 1 platelet count of ≥50 × 109/L to at least 1 of the following ITP treatments in the 3 years before the date of ICF signature: prednisone, dexamethasone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin
排除标准
- •Other than the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of ITP, confound the results of the study or put the participant at undue risk.
- •Secondary ITP
- •Nonimmune thrombocytopenia
- •Autoimmune hemolytic anemia
- •ITP-associated critical or severe bleeding The complete list of criteria can be found in the protocol.
研究组 & 干预措施
Efgartigimod IV
Experimental
Participants receiving efgartigimod IV during the double-blinded treatment period and the open-label treatment period(s)
干预措施: Efgartigimod IV (Biological)
Placebo IV
Experimental
Participants receiving placebo IV during the double-blinded treatment period and receiving efgartigimod IV during the open-label treatment period(s)
干预措施: Efgartigimod IV (Biological)
Placebo IV
Experimental
Participants receiving placebo IV during the double-blinded treatment period and receiving efgartigimod IV during the open-label treatment period(s)
干预措施: Placebo IV (Other)
结局指标
主要结局
Extent of disease control, defined as the number of cumulative weeks during the 24-week Double-Blinded Treatment Period with platelet counts of at least 50 × 10^9/L
时间窗: Up to 24 weeks
次要结局
- Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 6 of the 8 study visits between study weeks 17 and 24 of the DBTP(Up to 8 weeks)
- Efgartigimod Cmax over time(Up to 136 weeks)
- Proportion of participants achieving a platelet counts of at least 50 × 10^9/L for at least 8 of the 12 study visits between weeks 13 and 24 of the DBTP(Up to 12 weeks)
- Proportion of participants achieving a platelet count of at least 50 × 10^9/L on at least 4 occasions at any time until study week 12 during the DBTP(Up to 12 weeks)
- Time to response, defined as the time to achieve 2 consecutive platelet counts of at least 50 × 10^9/L at any time during the DBTP(up to 24 weeks)
- Proportion of participants with an IWG response during the DBTP(Up to 24 weeks)
- Proportion of participants with initial response, defined as a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count at study week 5 of the DBTP(Up to 20 weeks)
- Time to achieve a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count during the DBTP(Up to 24 weeks)
- Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and ≥20 × 10^9/L above baseline(Up to 24 weeks)
- Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline in participants with baseline platelet counts of <15 × 10^9/L(Up to 24 weeks)
- Extent of disease control, defined as the percentage of weeks with platelet counts of at least 50 × 10^9/L(Up to 76 weeks)
- In participants receiving placebo IV in the DBTP, the extent of disease control, defined as the number of cumulative weeks with platelet counts of at least 50 × 10^9/L(Up to 76 weeks)
- Overall platelet count response, defined as the proportion of participants achieving a platelet count of at least 50 × 10^9/L on at least 4 occasions during the first 52 weeks of treatment with efgartigimod IV(Up to 52 weeks)
- Mean change from baseline in platelet count at each study visit(Up to 76 weeks)
- The percentage of weeks with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline(Up to 76 weeks)
- In participants with baseline platelet counts <15 × 10^9/L, the percentage of weeks with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline(Up to 76 weeks)
- Proportion of participants who achieve a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10^9/L for at least 4 occasions during 6-week intervals(Up to 76 weeks)
- In participants receiving placebo IV in the DBTP, the proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 8 of the 12 study visits between weeks 13 and 24 of the OLTP1(Up to 12 weeks)
- In participants receiving placebo IV in the DBTP, proportion of participants who achieve sustained platelet count response, defined as achieving platelet counts of at least 50 × 10^9/L for at least 6 of 8 visits between weeks 17 and 24 of the OLTP1(Up to 8 weeks)
- In participants receiving placebo IV in the DBTP, the extent of disease control, defined as the number of cumulative weeks with platelet counts of at least 50 × 10^9/L during the first 24 weeks of treatment with efgartigimod IV(Up to 24 weeks)
- Occurrence rate of rescue ITP therapy(Up to 76 weeks)
- Proportion of participants with reduction in concurrent ITP therapy during the OLTP1(Up to 52 weeks)
- Incidence and severity of bleeding, assessed by the ITP Bleeding Scale (IBLS)(Up to 76 weeks)
- Incidence of NAb against efgartigimod in serum over time(Up to 136 weeks)
- Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 4 of the 6 study visits between study weeks 19 and 24 of the DBTP(Up to 6 weeks)
- Proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 6 of the 8 study visits between study weeks 17 and 24 of the DBTP(Up to 8 weeks)
- Proportion of participants achieving a platelet counts of at least 50 × 10^9/L for at least 8 of the 12 study visits between weeks 13 and 24 of the DBTP(Up to 12 weeks)
- Proportion of participants achieving a platelet count of at least 50 × 10^9/L on at least 4 occasions at any time until study week 12 during the DBTP(Up to 12 weeks)
- Time to response, defined as the time to achieve 2 consecutive platelet counts of at least 50 × 10^9/L at any time during the DBTP(up to 24 weeks)
- Proportion of participants with an IWG response during the DBTP(Up to 24 weeks)
- Proportion of participants with initial response, defined as a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count at study week 5 of the DBTP(Up to 20 weeks)
- Time to achieve a platelet count of at least 30 × 10^9/L and a 2-fold increase from baseline in platelet count during the DBTP(Up to 24 weeks)
- Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and ≥20 × 10^9/L above baseline(Up to 24 weeks)
- Number of cumulative weeks during the DBTP with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline in participants with baseline platelet counts of <15 × 10^9/L(Up to 24 weeks)
- Extent of disease control, defined as the percentage of weeks with platelet counts of at least 50 × 10^9/L(Up to 76 weeks)
- In participants receiving placebo IV in the DBTP, the extent of disease control, defined as the number of cumulative weeks with platelet counts of at least 50 × 10^9/L(Up to 76 weeks)
- Overall platelet count response, defined as the proportion of participants achieving a platelet count of at least 50 × 10^9/L on at least 4 occasions during the first 52 weeks of treatment with efgartigimod IV(Up to 52 weeks)
- Mean change from baseline in platelet count at each study visit(Up to 76 weeks)
- The percentage of weeks with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline(Up to 76 weeks)
- In participants with baseline platelet counts <15 × 10^9/L, the percentage of weeks with platelet counts of at least 30 × 10^9/L and at least 20 × 10^9/L above baseline(Up to 76 weeks)
- Proportion of participants who achieve a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10^9/L for at least 4 occasions during 6-week intervals(Up to 76 weeks)
- In participants receiving placebo IV in the DBTP, the proportion of participants achieving platelet counts of at least 50 × 10^9/L for at least 8 of the 12 study visits between weeks 13 and 24 of the OLTP1(Up to 12 weeks)
- In participants receiving placebo IV in the DBTP, proportion of participants who achieve sustained platelet count response, defined as achieving platelet counts of at least 50 × 10^9/L for at least 6 of 8 visits between weeks 17 and 24 of the OLTP1(Up to 8 weeks)
- In participants receiving placebo IV in the DBTP, the extent of disease control, defined as the number of cumulative weeks with platelet counts of at least 50 × 10^9/L during the first 24 weeks of treatment with efgartigimod IV(Up to 24 weeks)
- Occurrence rate of rescue ITP therapy(Up to 76 weeks)
- Proportion of participants with reduction in concurrent ITP therapy during the OLTP1(Up to 52 weeks)
- Incidence and severity of bleeding, assessed by the ITP Bleeding Scale (IBLS)(Up to 76 weeks)
- Incidence of AEs (including AEs of clinical interest) and SAEs(Up to 136 weeks)
- Incidence of ADA against efgartigimod in serum over time(Up to 136 weeks)
- Incidence of NAb against efgartigimod in serum over time(Up to 136 weeks)
- Efgartigimod Cmax over time(Up to 136 weeks)
- Percent change from baseline in total IgG levels in serum over time(Up to 136 weeks)
研究者
研究点 (178)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy VolunteersHealthy VolunteersNCT04564066argenx54
进行中（未招募）
3 期
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeNCT06684847argenx631
进行中（未招募）
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisGeneralized Myasthenia GravisMyasthenia GravisgMGNCT06298552argenx119
撤回
2 期
Evaluating Efgartigimod in Patients With Guillain-Barré SyndromeGuillain-Barre SyndromeNCT05701189Chafic Karam30
进行中（未招募）
2 期
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)Antibody-mediated RejectionNCT06503731argenx33